Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Karima Chafai"'
Autor:
Karima Chafai, Vanessa Balla, Hamida Oumbiche, Joël Ezenfis, Alfred Penfornis, Coralie Amadou
Publikováno v:
Annales d'Endocrinologie. 83:264-267
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53bae4473fc242856cbad905280b3267
https://doi.org/10.1016/j.ando.2022.02.004
https://doi.org/10.1016/j.ando.2022.02.004
Publikováno v:
Médecine des Maladies Métaboliques. 15:398-401
Resume L’hyperglycemie est un des effets secondaires les plus frequents de l’alpelisib, un inhibiteur de la sous-unite alpha de la phosphatidylinositol-3-kinase, utilise dans le traitement des cancers du sein metastatiques hormono-dependants avec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14e68cc9d0b2b67d618ea4552e48aa71
https://doi.org/10.1016/j.mmm.2021.03.003
https://doi.org/10.1016/j.mmm.2021.03.003
Publikováno v:
L'actualité Rhumatologique 2022 ISBN: 9782294778599
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b0e938f4ef4a82bffd79e75aaf17ab9
https://doi.org/10.1016/b978-2-294-77859-9.00020-7
https://doi.org/10.1016/b978-2-294-77859-9.00020-7
Autor:
Rabah Bensbaa, Karima Chafai, Alfred Penfornis, Anne Deburge, Hamida Oumbiche, Armelle Pochat, Coralie Amadou
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffc1af26b8eec5b1f93c798074e62686
https://doi.org/10.1530/endoabs.70.ep371
https://doi.org/10.1530/endoabs.70.ep371
Autor:
Takieddine Louifi, Coralie Amadou, Hadou Abdel Wedoud, Sebaa Rabah Ben, Alfred Penfornis, Pascaline Huynh, Rym Belaid, Karima Chafai
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f7695eaefa21ba214d7fb6679537e18
https://doi.org/10.1530/endoabs.63.ep90
https://doi.org/10.1530/endoabs.63.ep90
Autor:
Ashok Kumar, Sylvia A. Holden, Karima Chafai-Fadela, David P. Brennan, Siya Ram, Krishna Menon, Geoffrey I. Shapiro
Publikováno v:
Cancer Research. 77:3221-3221
Ovarian cancer (OC) is a molecularly and histologically heterogeneous disease; however, standard treatment is the same for all subtypes. High-grade serous OC initially responds to chemotherapy; however, low-grade serous and clear cell OC are relative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7bcff343611f6a190bd8afdca1c086e
https://doi.org/10.1158/1538-7445.am2017-3221
https://doi.org/10.1158/1538-7445.am2017-3221
Autor:
Geoffrey Shapiro, James Walter Mier, John Frederick Hilton, Leena Gandhi, Nicole G. Chau, Andrea J. Bullock, Jeffrey G Supko, Sigitas Jonas Verselis, Kayla Murgo, Cameron Sze, Susan Gotthardt, Andrew Wolanski, W. James Alexander, Ashok Kumar, Sylvia Adell Holden, Karima Chafai-Fadela, Siya Ram, Krishna E. Menon
Publikováno v:
Journal of Clinical Oncology. 33:TPS2613-TPS2613
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b894d4d75566a7b4a31d55774d3d5689
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2613
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2613
Publikováno v:
Annales d'Endocrinologie. 76:188
Introduction Thymic neuroendocrine (NE) tumors associated with multiple endocrine neoplasia type 1 (MEN-1) are rare, variably documented in 1–8% cases. They are malignant and aggressive tumors and constitute a major cause of mortality in MEN-1. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3681a380cca9a261f5a7ac89d3c6b10
https://doi.org/10.1016/j.ando.2015.03.034
https://doi.org/10.1016/j.ando.2015.03.034
Autor:
Geoffrey Shapiro, Jeffrey G Supko, Daniel C. Cho, John Frederick Hilton, Matthew Hadfield, Solida Pruitt-Thompson, Eveline Bordoli-Trachsela, Nela Zvereva, Andrew Wolanski, Aya Sato-DiLorenzo, Susan Gotthardt, Edward A. Fox, Sigitas Jonas Verselis, Ashok Kumar, Sylvia A. Holden, Siya Ram, Karima Chafai-Fadela, Kimberly Harding, Krishna E. Menon
Publikováno v:
Journal of Clinical Oncology. 31:TPS2627-TPS2627
TPS2627 Background: Thioureidobutyronitrile, kevetrin, has demonstrated anti-tumor activity in several wild type and mutant p53 human tumor xenografts without evidence of genotoxicity. In wild type p53 models, kevetrin induces cell cycle arrest and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2ed18dacf588aff25ffc07a91e032d8
https://doi.org/10.1200/jco.2013.31.15_suppl.tps2627
https://doi.org/10.1200/jco.2013.31.15_suppl.tps2627
Publikováno v:
Cancer Research. 72:2874-2874
Our studies showed that Kevetrin™, a small molecule currently under development, has potent antitumor activity in several wild type and mutant p53 human tumor xenografts e.g. A549, PC-3, MDA-MB-231, HT-29, NCI-H1975, HCT-15, K-562, LNCaP. To invest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8a073d2fd7c075b6ae5bfd38711bab1
https://doi.org/10.1158/1538-7445.am2012-2874
https://doi.org/10.1158/1538-7445.am2012-2874